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Background: We found that 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) uptake in malignant lesion was enhanced,
and it was decreased in the inflammatory lesion after the use of peroxisome proliferator activated receptor-γ
(PPAR-γ) agonist in our previous preclinical study. The purpose of this study was to investigate the effect of PPAR-γ
agonist on malignant lesions in clinical 18F-FDG positron emission tomography/computed tomography (PET/CT)
imaging.
Methods: Forty-three patients were enrolled in this prospective study. We received the approval for the
investigator-initiated trials for a phase II human clinical trial from the Korean Food and Drug Administration. On the
first day, 18F-FDG PET/CT images were acquired from patients without administration of pioglitazone (PIO), which is a
PPAR-γ agonist. On the next day, 18F-FDG PET/CT images were acquired once again from the same patients after
administration of PIO. We measured the 18F-FDG uptake in malignant lesions or inflammatory lesions from two
18F-FDG PET/CT images. Four different PET parameters were used to compare between the two studies: SUVmax,
SUVmean, average activity over 30 % of the isocontour (isocontour, Bq/mL), and isocontour-mediastinal activity
(Bq/mL). Additionally, we classified the patients into two groups: the responder or non-responder group according
to the presence of PIO effect on skeletal muscle. Furthermore, PET parameters of malignant lesions were analyzed
based on the type of malignancy and were compared with those of inflammatory lesions.
Results: All four PET parameters of malignant lesions in the responder group showed increasing patterns after the
use of PIO. In the subgroup analysis, the similar pattern was observed in gastrointestinal cancer. In hepatobiliary and
pancreatic cancer, SUVmean and isocontour showed statistically significant increase in the presence of PIO. On the
other hand, in the non-responder group, all four PET parameters showed decreasing patterns in both malignant
and inflammatory lesions after the use of PIO. There was no statistically significant difference in PET parameters of
malignant lesions in the non-responder group.
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Conclusions: In this study, we found that PIO had the potential to increase 18F-FDG uptake of malignant lesions in
the patients who showed PIO effect on skeletal muscle. Contrary to our preclinical studies, clinical results had
limitations to evaluate malignant lesions in non-responder group. Further larger-scale studies are necessary to
elucidate the potential role of PIO on 18F-FDG uptake in malignant or inflammatory lesions.
Trial registration: The test for safety and effectiveness of the new efficacy of Pioglitazone to diagnose the malignant
tumor and inflammation in F-18 FDG positron emission tomography (PET) study, 12029
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Peroxisome proliferator activated receptors (PPARs) are
members of the ligand-activated nuclear receptor
superfamily which initiate transcription of an array of
genes that are involved in energy homeostasis [1, 2]. So
far, three major types of PPARs have been identified
and each receptor controls transcription by binding to
specific DNA elements: PPAR-α, associated with lipid
metabolism; PPAR-β/δ, associated with energy homeo-
stasis; and PPAR-γ, associated with glucose metabolism
[3–5]. Transcriptional regulation by PPARs requires het-
erodimerization with the retinoid X receptor (RXR), and
the dimer binds to specific DNA sequence elements called
a peroxisome proliferator response element (PPRE) in the
promoter region of target genes [6–9].
A wide variety of natural or synthetic compounds were
identified as PPAR ligands [6]. Among the synthetic ligands
that selectively activate PPAR-γ, thiazolidinedione is an
insulin sensitizer that is used to treat hyperglycemia in type
2 diabetes [6, 10]. It reduces insulin resistance in adipose
tissue, muscle, and liver [11–14]. Due to improvement in
insulin sensitivity, glucogenesis in the liver is decreased
and glucose uptake in the peripheral tissues is increased.
Currently, two types of thiazolidinediones are commer-
cially available in the market, namely troglitazone and pio-
glitazone (PIO) [15, 16].
Recently, many researches have demonstrated the
anti-inflammatory effects of PPAR receptor [17, 18].
PPAR-γ receptor is expressed in many cell types both
within and outside the immune system. Synthetic PPAR-
γ agonists including pioglitazone repress the production
of inflammatory cytokines in immune-related cells
such as CD4+ T cells and monocytes [19]. These reports
suggest that PPAR-γ agonists have anti-inflammatory
function.
18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) is a radio-
pharmaceutical analog of glucose that is used for diagnosis
of cancer with increased glucose metabolism. However,
18F-FDG uptake is not only found in malignant lesions
but also in inflammatory lesions [20–23]. Therefore,
inflammatory lesions are likely to be mistaken as malig-
nant lesions owing to intense accumulation of 18F-FDG.
Because glucose is the primary metabolic substrate ofmacrophages, immune reaction requires glucose import,
primarily through the glucose transporter (Glut) [24].
The effects of PPAR-γ agonist on the peripheral tissue
made us curious about how they act on malignant lesions.
Other function of PPAR-γ agonists that cause suppres-
sion of immune related cells suggests that they may
have potential effects on inflammatory lesions. These
concepts made us investigate the pharmacological effects
of PPAR-γ agonists in preclinical research. In our previous
cell and animal studies, we found that rosiglitazone
induced Glut 1 in various malignant cells but not in in-
flammatory cells [25]. Furthermore, in 18F-FDG PET/CT
images of mouse models, increased 18F-FDG uptake was
observed in malignant models but not in inflammatory
models after administration of PIO [26].
To the best of our knowledge, these effects of PPAR-γ ag-
onists have not been evaluated in human 18F-FDG PET/CT
images so far. The purpose of this study is to evaluate the
effect of PIO on 18F-FDG uptake in malignant or inflamma-
tory lesions in clinical 18F-FDG PET/CT imaging.
Methods
Patients
This was a prospectively designed study. From December
2012 to July 2013, patients who were diagnosed or sus-
pected to have malignant or inflammatory lesions were
enrolled at Chonbuk National University Hospital. Exclu-
sion criteria for patients were hypersensitivity to PIO,
insulin-dependent diabetes mellitus, diabetic ketoacidosis,
active liver disease, or alanine aminotransferase >2.5 times
of the upper normal limit, heart failure, and renal insuffi-
ciency. Finally 43 patients (30 men and 13 women,
mean age, 64.0 ± 11.8 years) were enrolled in this
study. Laboratory examinations were performed before
and after administration of PIO, and the results were
compared for toxicity assessment data. They included
serum alanine aminotransferase, aspartate aminotransfer-
ase, total bilirubin, direct bilirubin, blood urea nitrogen,
creatinine, uric acid, cholesterol, and lactate dehydrogen-
ase. We received the approval for the investigator-initiated
trials for a phase II human clinical trial from the Korean
Food and Drug Administration. This prospective study
was approved by the Institutional Review Board. All
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gave written informed consent.
18F-FDG PET/CT protocol
On the first day, 18F-FDG PET/CT images were acquired
from patients in the absence of PIO. All patients fasted for
at least 6 h prior to the intravenous injection of 18F-FDG,
and blood glucose levels in all patients were found to be
below 126 mg/dL. Approximately 5.5 MBq of 18F-FDG per
kilogram of body weight was administered intravenously.
Scanning was performed 60 min after 18F-FDG administra-
tion. Images were obtained from the base of the skull to
the proximal thigh by using either a Biograph TruePoint
40 PET/CT scanner (Siemens Medical Solutions, Knoxville,
TN, USA) or a Biograph 16 PET/CT scanner (Siemens
Medical Solutions, Knoxville, TN, USA). All patients were
placed in the supine position with their both arms raised.
A low-dose CT scan was obtained first for attenuation cor-
rection by using a continuous spiral technique (120 kVp,
45 mA, 0.5 s rotation time). A PET scan was then acquired
in a 3-dimensional mode for 2–3 min per bed position.
After the acquisition of PET data, the patient underwent a
diagnostic CT scan with intravenous contrast (120 kVp,
200 mA, 0.5 s rotation time). The obtained PET data were
reconstructed iteratively using an ordered-subset expect-
ation maximization algorithm (128 × 128 matrix, 3.27 mm
slice thickness, subset: 21, iterations 2). The next day, pa-
tients took PIO orally 2 h prior to 18F-FDG PET/CT ac-
quisition because time of peak plasma concentration of
PIO is about 2 h. PET/CT images were obtained once again
by the same 18F-FDG PET/CT protocol without contrast
media. 18F-FDG PET/CT images of each patient were
acquired by using the same PET/CT scanner.
18F-FDG PET/CT image analysis
18 F-FDG uptake in malignant or inflammatory lesions
was measured from two 18 F-FDG PET/CT images. Malig-
nant lesions were selected up to three in a patient. Because
some patients had lots of malignant lesions, we limited the
number of lesions in a patient. Benign lesion was selected
up to two in a patient. We placed VOI (volume of interest)
on the tumors and inflammatory lesions based on CT in-
formation. Four different PET parameters were measured
to compare the two studies: SUVmax, SUVmean (threshold
SUV, 3), average activity over 30 % of the isocontour (iso-
contour, Bq/mL), and isocontour-mediastinal activity (Bq/
mL). Mediastinal activity was measured in the ascending
aorta as a standard background activity.
We classified the patients into two groups: the responder
or non-responder group according to the presence of PIO
effect by measuring thigh muscle uptake. Average activity
in thigh muscle was obtained from a volume of interest
placed over an area of homogenous activity in the adductor
muscles. Care was taken to avoid large vascular structuresand any areas of increased 18F-FDG uptake that might rep-
resent malignancy. The way to measure thigh muscle activ-
ity is shown in Fig. 1.
Patients who showed increased activity (average activ-
ity measured as Bq/mL) in the thigh muscle after admin-
istration of PIO were classified into the responder
group. The other patients who showed no change or
decreased activity in the thigh muscle were classified
into the non-responder group. We calculated the per-
centage of difference of the PET parameters from the
two studies in the same patient. Next, PET parameters
of malignant lesions were analyzed based on the type of
primary malignancy and were compared with those of
inflammatory lesions.
Malignant and inflammatory lesions were enrolled
and analyzed by two nuclear physicians. Any equivocal
lesions which were confused as tumors or inflammatory
lesions were excluded. Because four different PET param-
eters and mediastinal activity were measured automatically,
there were almost no disagreements between two nuclear
physicians. Few parameters were different but showed
similar values. They were applied as their average values.
Statistical analysis
Paired t test and Wilcoxon signed rank test were used to
evaluate the differences in PET parameters in same
lesions. Mann-Whitney U test was performed for com-
paring the parameters of malignant and inflammatory
lesions. Any lesion which showed difference more than 1
standard deviation was regarded as a meaningful change.
Statistical analysis was performed using SPSS software
(version 12.0). Statistical significance was defined as a
P value less than 0.05.
Results
Patient characteristics
Forty-three patients from Chonbuk National University
Hospital were recruited in this prospective study. Mean
age of patients was 64.0 years. There were various types
of malignancies: cancers of the hepatobiliary tree and
pancreas (except for hepatocellular carcinoma), lung,
liver (hepatocellular), colorectum, stomach, esophagus,
and kidney. Benign lesions included mediastinal lymph
node, pneumonia, rib fracture, and liver cyst. Patient
details are summarized in Table 1.
Of the 43 patients, 29 patients who showed increased
FDG uptake in the right thigh muscle after administra-
tion of PIO were classified into the responder group.
The other 14 patients who did not show increased FDG
uptake were categorized into the non-responder group.
Average activity of the thigh muscle increased from
2346.57 ± 554.26 to 2986.24 ± 689.45 Bq/mL in responder
group. In non-responder group, it decreased from
2457.33 ± 386.55 to 2173.23 ± 324.04 Bq/mL.
Fig. 1 Measurement of the thigh muscle activity. Volume of interest is placed over an area of homogenous activity in the adductor muscles.
Average activity in the thigh muscle is 3360.11 Bq/mL
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age activity in left ventricle. Myocardial activity changed
from 8433.25 ± 2816.97 to 8768.34 ± 2184.25 Bq/mL in
responder group and from 8941.13 ± 2247.61 to 8845.67 ±
2713.55 Bq/mL in non-responder group. There were no
significant differences both when comparing two groups
and comparing two different days.
In comparison of fasting blood glucose level and
body mass index between responder and non-responder
groups, significant differences were not observed.
Fasting blood glucose levels in responder group chan-
ged from 91.67 ± 16.10 to 89.24 ± 19.31 mg/dL, and
those of non-responder group changed from 89.32 ±Table 1 Characteristics of patients
Characteristics
Age (mean ± SD, year) 64.0 ± 11.8
Sex (M:F) 30:13




Hepatobiliary and pancreatic cancer 18/9 6/4
Hepatocellular carcinoma 7/6 5/4
Colorectal cancer 7/5 2/1
Gastric cancer 4/4 7/4
Esophageal cancer 3/1 2/1
Renal cell carcinoma 2/1 –
Duodenal GIST 1/1 –
Lung cancer – 1/118.66 to 84.86 ± 13.98 mg/dL. Body mass index (BMI)
was calculated by dividing weight in kilograms by
the square of height in meters. They were 23.11 ±
3.06 kg/m2 in responder group and 21.71 ± 2.56 kg/m2 in
non-responder group.
We recommend the dose of PIO two tablets (30 mg)
to the patients enrolled; however, some of them did not
easily accept the two tablets and wanted to take one
tablet (15 mg). Therefore, 13 patients were administered
one tablet of PIO (15 mg) and the other 30 patients took
two tablets of PIO (30 mg). Most patients showed
slightly lower plasma glucose level after administration






Mediastinal lymph node 9/7 4/3
Pneumonia 1/1 –
Rib fracture – 1/1
Liver cyst – 1/1
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PIO.
Analysis of PET parameters
Forty-two malignant lesions and 10 benign lesions in the
responder group and 23 malignant lesions and 6 benign
lesions in the non-responder group were analyzed by using
the following four different PET parameters: SUVmax,
SUVmean, isocontour, and isocontour-mediastinal activity.
All four PET parameters of malignant lesions in the
responder group showed increasing patterns after the use
of PIO. In the subgroup analysis, the similar patterns were
observed in gastrointestinal cancer. In hepatobiliary and
pancreatic cancer (except for hepatocellular carcinoma),
SUVmean and isocontour showed a statistically significant
increase in the presence of PIO. Hepatocellular carcin-
oma showed increasing patterns of PET parameters,
but these were not statistically significant. Statistically
useful parameters were different depending on the type of
primary malignancy. In inflammatory lesions, SUVmean
and isocontour-mediastinal activity showed decreasing
patterns and isocontour-mediastinal activity showed the
most apparent decrease after the use of PIO. On compari-
son of the percentage of difference between malignant
and inflammatory lesions, isocontour of malignant lesions
showed statistically significant differences. This parameter
was considered to have differential power to dichotomize
lesions into malignancy versus inflammation. The percent-
age of difference and the changing patterns of PET param-
eters in the responder group are shown in Table 2 and
Fig. 2. Figure 3 is 18F-FDG PET/CT images of a patient
who have malignant lesions.
In the non-responder group, all four PET parameters
showed decreasing patterns in both malignant and
inflammatory lesions after the use of PIO. There was no
statistically significant difference in PET parameters of
malignant lesions. In inflammatory lesion, isocontour,
and isocontour-mediastinal activity showed statistically
significant decrease after use of PIO. The % difference
and the changing patterns of PET parameters in the
non-responder group are shown in Table 3 and Fig. 4.
Contrary to our previous preclinical studies, in com-
parison of PET parameters between one tablet (15 mg)Table 2 Percentage of difference of PET parameters in responder gr
Type of lesions SUVmax SUVmean
Malignant lesion 13.82* 9.49*
Gastrointestinal cancer 25.94* 9.69
Hepatobiliary and pancreatic cancer 5.89 10.71*
Hepatocellular carcinoma 7.48 3.98
Inflammatory lesion 5.95 −1.27
*P < 0.05 when compared parameters between the first day and second day
**P < 0.05 when compared with difference (%) of inflammatory lesiongroup and two tablets (30 mg) group, PET parameters
did not show dose-dependent manners.
Additionally, in analyzing tumor features on CT such
as size and enhancement pattern, there were no specific
relationships with four different PET parameters.
Discussion
The thiazolidinediones or “glitazones” are one class of
oral antidiabetic drugs that improve insulin sensitivity in
patients with type 2 diabetes [27]. In our previous pre-
clinical study, higher 18F-FDG uptake was observed after
the injection of rosiglitazone in malignant xenograft
mice, but no significant change was observed in inflam-
matory xenograft mice. We found that rosiglitazone had
the potential to increase the contrast between malignant
and inflammatory lesions. Some studies have however
reported that rosiglitazone is associated with an increased
risk of heart attack and hear failure [28, 29]. In 2010, the
FDA took a cautious stance and limited exposure to rosi-
glitazone [30]. The rosiglitazone discontinuation rate
increased following the FDA warning, and currently,
rosiglitazone is almost pulled out of the market [31].
Therefore, a preclinical study using PIO rather than
rosiglitazone was performed to investigate the differ-
ential effects on malignant and inflammatory lesions.
We also found that 18F-FDG uptake was increased in
response to PIO treatment in malignant cells in a dose-
dependent manner, while 18F-FDG uptake was decreased
in macrophages. In vivo studies also showed that 18F-FDG
uptake (%ID/g) in malignant lesions was increased by 1.5-
fold and 18F-FDG uptake (%ID/g) in inflammatory lesions
was decreased by 1.8-fold after treatment with PIO.
Based on these preclinical results, we established the
clinical study design to assess the PIO effect in differ-
entiating malignant lesions from inflammatory lesions
on 18F-FDG PET imaging. Forty-three patients were
enrolled in this study and they underwent 18F-FDG
PET/CT twice in the absence and presence of PIO. We
chose the thigh muscle as a reference region to valid-
ate the action of PIO. This was because the thigh muscle
was considered to be less affected by the patient’s tension
or cold environment and wide enough for measuring the







Fig. 2 Changing patterns of PET parameters in the responder group. a, b Isocontour and SUVmean show increasing pattern in malignant lesions
after the use of pioglitazone. c, d In hepatobiliary cancer, 12 out of the 18 lesions show increasing patterns of SUVmean. Four out of the 12
increase more than 1 SD. e In gastrointestinal cancer, 14 out of the 15 lesions have increasing patterns of isocontour. Six out of the 14 lesions
show significant increase more than 1 standard deviation (SD). f On the other hand, in inflammatory lesions, there is no statistically
significant increase
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blood, the thigh muscle activity on 18F-FDG PET imaging
should increase after the use of PIO. Twenty-nine patients
(67.4 %) showed increased muscular activity, but the other
14 patients (32.6 %) did not show increased muscular
activity after treatment with PIO. The findings of 14 non-
responder patients could be explained by the fact that all
of these patients had a low-fasting blood glucose level
<126 mg/dL, and PIO action probably might not be neces-
sary to decrease the blood glucose level by transportingblood glucose into the peripheral tissue in some patients.
This could be a possible reason why there were no statisti-
cally significant differences in PET parameters in the non-
responder group.
Interestingly, there were some patients who showed
decreasing patterns of PET parameters in malignant
lesions, regardless of the presence of the PIO effect.
Generally, malignant tumor tissues include not only can-
cer cells but also host stromal cells (e.g., fibroblasts,
macrophages, lymphocytes, etc.) [32]. 18F-FDG uptake
Fig. 3 A 52-year-old woman with gastric cancer and multiple lymph nodes metastases. a, b and c Before administration of pioglitazone, SUVmean
and isocontour of gastric cancer in 18F-FDG PET/CT image were 3.09 and 6824.52 Bq/mL. d, e and f After administration of pioglitazone, they
were increased to 3.78 and 9480.92 Bq/mL. In both maximum-intensity-projection and axial PET/CT images, glucose metabolism in gastric cancer
and metastatic paraaortic lymph node shows increasing pattern on the next day after the use of pioglitazone. This patient also has both supraclavicular
and right mediastinal lymph nodes metastases
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might decrease in tumor tissues, which include a large
proportion of inflammatory cells, after the use of PIO.
However, further investigations are required to elucidate
the relationship between intratumoral heterogeneity and
PIO effect.
We measured four different PET parameters: SUVmax,
SUVmean, average activity over 30 % of the isocontour(isocontour), and isocontour-mediastinal activity. These
parameters could be easily measured on a workstation
without any expensive or complicated software. All of
these four PET parameters were increased in malignant
lesions, and the same patterns were observed in the sub-
group analysis of gastrointestinal cancer. In the sub-
group analysis of hepatobiliary and pancreatic cancer,
SUVmean and isocontour showed statistically significant
Table 3 Percentage of difference of PET parameters in non-responder group
Type of lesions SUVmax SUVmean Isocontour (Bq/mL) Isocontour-mediastinalactivity (Bq/mL)
Malignant lesion −4.71 −4.89 −16.36 −12.98
Gastrointestinal cancer −5.88 −4.68 −11.64 −8.74
Hepatobiliary and pancreatic cancer −6.71 −4.64 −17.34 −8.48
Hepatocellular carcinoma −1.64 −5.30 −25.52 −26.99
Inflammatory lesion −10.21 −6.17 −32.22* −45.70*
*P < 0.05 when compared parameters between the first day and second day
Fig. 4 a, b, c, d, e, f Changing patterns of PET parameters in the non-responder group. The PET parameters show decreasing patterns in both
malignant and inflammatory lesions after the use of PIO. There are no significant differences
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gest that the useful PET parameters would be different
depending on the type of primary malignancy. A fur-
ther study in a large number of patients is necessary to
establish the specific diagnostic protocol.
The Korean FDA allowed us to administer a PIO dose
up to three tablets (45 mg) in each patient. The dosage of
PIO was recommended 30 mg to provide same pharmaco-
logical condition to the enrolled patients; however, 13
patients wanted to take one tablet (15 mg), and the other
30 patients took two tablets (30 mg) of PIO. In compari-
son of PET parameters between one tablet group and
two tablets group, PET parameters did not show dose-
dependent manners. Prolonged use of PIO has been
known sometimes to bring several side effects: anemia,
hypoglycemia induced symptoms such as palpitation,
dizziness, diaphoresis, congestive heart failure, pulmon-
ary edema, and myocardial ischemia. Patients in this
study were administered PIO only once, and the max-
imum dose was 30 mg. None of the patients suffered
from adverse effects of PIO. On comparison of labora-
tory data obtained before and after the study, we could
not find any clinically adverse changes after the use of
PIO. Based on these results, we can carefully deduce
that PIO could be safely applied in the clinical field.
This study has several limitations. Firstly, not all of
the lesions were histopathologically confirmed. Pri-
mary malignant sites were confirmed by biopsy, but
metastatic lymph nodes and metastases in other organs
were mostly diagnosed based on serial follow-up.
Twenty-four out of 42 malignant lesions and 4 out of
10 benign lesions in responder group and 11 out of 23
malignant lesions and 2 out of 6 benign lesions in non-
responder group were confirmed by histopathologic
study. The other lesions were determined as malignant
or benign by serial follow-up for at least 1 year. The
second limitation is the small sample size of benign
lesions. Because we could enroll patients who had
malignancies, benign lesions were searched in 18F-FDG
PET/CT images of the same patients. The small sam-
ple size of benign lesions might be a possible reason
for statistically insignificant values of some important
parameters. The third limitation is that lesions in non-
responders could not be evaluated as either benign or
malignant lesions using these study results. Therefore,
a further study in a larger cohort is needed. Further
larger-scale study is required to evaluate day-to-day
variability of thigh muscle uptake, optimal dose and
time of PIO administration, and the effects of other
conditions such as oral absorption of PIO, distribution
volume, metabolic syndrome, or the severity of the
underlying disease.
In spite of these limitations, this study is valuable as it
is the first study to investigate PIO effect on 18F-FDGuptake in malignant or inflammatory lesions in clinical
18F-FDG PET/CT images. In addition, we provide a spe-
cific parameter which might be useful to differentiate
malignant lesions from inflammatory lesions. We also
found that 18F-FDG PET technology is a very sensitive
tool to show the effect of pharmacologic action on spe-
cific target organ. In this study, non-responders who did
not show increased 18F-FDG uptake in muscle against
PIO effect did not show the increased tumor uptake,
either. From this point, we think that PET technology can
provide us visual and quantitative information whether a
drug would work properly or not.
Conclusions
Although results showed at our preclinical studies had not
been drawn in non-responder group and further larger-
scale studies are necessary to generalize the potential role
of PIO on 18F-FDG uptake in all patients, we found that
PIO had the potential to increase 18F-FDG uptake in
malignant lesions in the patients who showed PIO effect
on thigh muscle.
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